Gabapentin showed significant linear dose effects on craving, mood, and sleep (Figure 4a–c). Over the course of treatment, significant dose-dependent reductions were obtained on the Alcohol Craving Questionnaire (F=3.56, df=2, p=0.029; gabapentin 1800mg v. placebo: −6.80 [95% CI, −1.50 to −12.1], t=−2.52, p=0.012) the Beck Depression Inventory II (F=7.37, df=2, p=0.001; gabapentin 1800mg v. placebo: −1.13 [95% CI, −2.0 to −0.27], t= −2.57, p=0.010), and the Pittsburgh Sleep Quality Index total score (F=136, df=2, p<0.001; gabapentin 1800mg v. placebo: −1.49 [95% CI, −2.14 to −0.83], t=−4.46, p<0.001).
